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Abstract	84 
Trypanosoma	brucei	gambiense	causes	human	African	trypanosomiasis	(HAT)	in	West	and	85 
Central	Africa.	Between	1990	and	2015,	almost	440,000	cases	were	reported.	Thanks	to	86 
large-scale	screening	of	populations	at	risk,	drug	donations	and	efforts	by	national	and	87 
international	stakeholders,	the	epidemic	has	been	brought	under	control	with	<	2200	cases	88 
reported	in	2016.	The	World	Health	Organization	has	set	the	goals	of	gambiense-HAT	89 
elimination	as	public	health	problem	for	2020	and	interruption	of	transmission	to	humans	90 
for	2030.	Factors	that	challenge	the	sustained	elimination	of	gambiense-HAT	are	latent	91 
human	infections	and	possible	animal	reservoirs,	in	particular	among	domestic	animals.	92 
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Recent	studies	have	increased	our	knowledge	on	both	phenomena	but	it	remains	unknown	93 
whether	they	have	an	impact	on	the	epidemiology	of	gambiense-HAT,	and	if	they	have,	how	94 
important	that	impact	is	in	view	of	the	elimination	goal.	Here,	we	argue	that	a	better	95 
understanding	of	the	contribution	of	human	and	putative	animal	reservoirs	to	the	96 
gambiense-HAT	epidemiology	is	required	to	inform	elimination	strategies.	97 
	 	98 
6 
 
Can	cryptic	reservoirs	in	humans	and	animals	compromise	the	sustainable	elimination	of	99 
gambiense-human	African	trypanosomiasis?	100 
Human	African	trypanosomiasis	(HAT)	(see	Glossary)	is	caused	by	two	closely	related	101 
parasites	that	are	transmitted	by	tsetse	flies.	Trypanosoma	brucei	gambiense	is	responsible	102 
for	the	Western	and	Central	African	form	of	the	disease	and	Trypanosoma	brucei	103 
rhodesiense	occurs	in	Eastern	and	Southern	Africa	-	both	forms	of	the	disease	are	usually	104 
fatal	if	untreated.	Between	1990	and	2016,	a	total	of	437,971	cases	of	gambiense-HAT	were	105 
reported,	with	a	peak	of	37,385	cases	in	1998	106 
(http://www.who.int/gho/neglected_diseases/human_african_trypanosomiasis/en/).	107 
Thanks	to	large-scale	deployment	of	a	serological	screening	test	(CATT/T.b.	gambiense),	108 
drug	donations	and	intense	efforts	by	national	and	international	stakeholders,	this	epidemic	109 
has	been	brought	under	control	with	fewer	than	2200	cases	reported	in	2016.	This	110 
represents	a	marked	reduction	in	human	suffering	caused	by	the	disease.	Inspired	by	this	111 
progress,	the	World	Health	Organization	(WHO)	has	set	elimination	of	gambiense-HAT	as	a	112 
target	for	the	near	future:	elimination	as	a	public	health	problem	by	2020	and	the	113 
interruption	of	transmission	to	humans	by	2030	114 
(http://apps.who.int/iris/bitstream/10665/70809/1/WHO_HTM_NTD_2012.1_eng.pdf).		115 
The	rationale	to	shift	from	HAT	control	to	elimination	is	based	on	several	arguments,	such	as	116 
the	epidemiological	vulnerability	of	gambiense-HAT	as	a	presumed	anthroponotic	infection,	117 
historic	examples	of	elimination	in	several	West	African	foci,	the	availability	of	medicines	118 
and	diagnostics,	the	political	will	of	endemic	countries	and	the	commitment	of	national	119 
control	programs	[1].	Furthermore,	a	drug	donation	agreement	between	pharmaceutical	120 
companies	and	WHO	has	made	treatment	freely	available	to	endemic	countries.		121 
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Gambiense-HAT	control	classically	relies	on	3	pillars:	vector	control,	diagnosis	and	122 
treatment.	HAT	is	a	vector-borne	disease,	and	the	reduction	of	human-fly	contact	below	a	123 
critical	threshold	would	lead	to	zero	transmission.	Although	vector	control	is	critical	to	124 
achieve	the	elimination/eradication	goals,	it	will	not	be	practical	to	sustainably	control	all	125 
tsetse	fly	populations	in	all	endemic	countries.	Vector	control	being	only	part	of	the	126 
solution,	gambiense-HAT	control	will	continue	to	rely	to	a	great	extent	on	diagnosis	and	127 
treatment,	both	for	reducing	transmission	and	for	monitoring	progress	towards	these	goals.		128 
The	introduction	of	individual	rapid	diagnostic	tests	(RDTs)	for	gambiense-HAT	may	increase	129 
serological	screening	coverage,	as	they	can	be	performed	in	remote	dispensaries	devoid	of	130 
technical	facilities.	Thus,	they	facilitate	integration	of	passive	screening	in	the	health	system	131 
and	assist	in	establishing	a	sustainable	surveillance	system.	However,	RDTs	also	have	132 
limitations	-	like	CATT/T.b.	gambiense,	they	only	detect	antibodies,	and	their	specificity	is	133 
not	100%	[2].	As	a	consequence,	given	the	adverse	effects	and	logistic	constraints	of	current	134 
treatment,	individuals	who	test	positive	in	an	RDT	or	in	CATT	must	undergo	microscopic	135 
examination	of	blood	or	lymph	node	fluid	to	confirm	the	presence	of	the	parasite,	followed	136 
by	a	lumbar	puncture	for	stage	determination	as	different	drugs	are	required	to	treat	early	137 
and	late	stage	disease	[1].	In	recent	years,	the	highly	toxic	melarsoprol	regimen,	used	to	138 
treat	late	stage	disease,	has	been	replaced	by	a	safer	though	still	rather	complex	treatment,	139 
requiring	parenteral	administration	and	hospitalisation.	An	oral	treatment	might	become	140 
available	in	late	2018	and	a	single-dose	treatment	is	entering	phase	III	clinical	trials	141 
(http://www.dndi.org/diseases-projects/hat/portfolio/).	142 
Whereas	HAT	elimination	as	a	public	health	problem	by	2020	seems	within	reach,	the	143 
sustained	global	elimination	of	HAT	appears	more	challenging.	Indeed,	as	long	as	the	144 
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knowledge	gaps	surrounding	the	reservoir	of	T.b.	gambiense	in	inter-epidemic	periods	are	145 
not	filled,	the	concept	of	eradication	of	gambiense-HAT	cannot	be	considered.		146 
We	present	the	current	research	evidence	about	potential	human	and	animal	T.b.	147 
gambiense	reservoirs	and	discuss	their	importance	in	the	light	of	the	gambiense-HAT	148 
elimination	goals.	149 
Human	reservoir	150 
Mathematical	models	show	that	the	sustained	transmission	of	HAT	can	be	explained	if	a	151 
fraction	of	the	HAT	cases	are	systematically	missed	by	the	screening	operations	[3].	152 
Unfortunately,	this	is	the	case	in	many	settings,	as	a	number	of	T.b.	gambiense	infections	153 
remain	undiagnosed	for	several	reasons	[4].	First,	not	all	infected	people	are	reached	by	154 
screening	activities.	Second,	actually	applied	diagnostic	techniques	do	not	pick	up	all	T.b.	155 
gambiense	infections	due	to	lack	of	sensitivity	of	serological	screening	tests,	molecular	156 
techniques	or	of	the	parasitological	confirmation	tests	[5].	These	undiagnosed,	yet	infected	157 
people,	will	act	as	a	human	reservoir	of	the	parasite	and	might	sustain	transmission,	forming	158 
a	maintenance	population	[6].	Still	another	potential	category	of	human	reservoir	may	159 
consist	of	latent	infections,	also	called	‘healthy	carriers’,	who	do	not	always	progress	to	160 
clinical	disease,	though	the	relative	contribution	of	these	individuals	to	parasite	161 
transmission	still	needs	to	be	documented	(BOX	1).	These	latently	infected	people	may	carry	162 
trypanosomes	for	years	or	even	decades,	as	was	first	described	half	a	century	ago	in	West	163 
Africa	and	later	in	patients	refusing	treatment	in	Côte	d’Ivoire	[7,8].	More	recently,	a	HAT	164 
case	with	a	latent	infection	of	at	least	29	years	was	documented	[9].	In	Guinea,	165 
asymptomatic	or	latent	infections	were	found	to	have	consistently	high	titres	in	CATT/T.b.	166 
gambiense	and	to	be	positive	in	the	immune	trypanolysis	test,	although	no	parasites	could	167 
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be	detected	in	blood	or	lymph	node	fluid	during	a	two-year	follow-up	period	[10].	This	168 
observation	is	in	line	with	the	fact	that	trypanosomes	can	survive	in	the	extravascular	spaces	169 
of	diverse	organs	such	as	the	heart,	the	central	nervous	system	and	the	skin	[11-13].	170 
Experimental	infections	in	animals	confirmed	that	parasites	may	be	undetectable	in	the	171 
blood	but	hidden	in	different	organs	and	tissues,	[14-17]	including	the	skin,	from	where	they	172 
can	be	ingested	by	tsetse	flies	[18,19].	It	is	only	recently	that	researchers	began	to	173 
investigate	the	underlying	host-parasite	interaction	mechanisms	responsible	for	those	latent	174 
infections.	Microsatellite	profiles	and	genomic	sequencing	of	parasites	from	latent	175 
infections	and	from	clinical	HAT	patients	are	indistinguishable,	suggesting	that	the	latent	176 
infection	phenotype	is	determined	primarily	by	the	host	rather	than	by	the	parasite	[20].	177 
Studies	on	host	genetic	polymorphism	show	that	TNFA-308	A,	HLA-G	UTR-2,	APOL1	N264K	178 
and	APOL1	G2	are	associated	with	increased	risk	of	infection	or	with	disease	progression,	179 
while	IL10-592	A,	IL64339,	APOL1	G1	and	other	polymorphisms	in	HRP	and	APOL1	are	180 
associated	with	decreased	risk	of	infection	or	with	latent	infection	[21-26].	Other	studies	181 
have	found	associations	between	the	innate	and	the	adaptive	immune	response	and	182 
infection	outcome,	e.g.	self-cure	and	high	levels	of	IL8;	latent	infection	and	high	levels	of	IL6	183 
or	specific	IFNG	producing	T	cells;	disease	progression	and	high	levels	of	IL10,	TNFA	and	184 
sHLA-G	[27-29].	In	view	of	the	global	elimination	of	HAT,	it	is	of	utmost	importance	to	clarify	185 
the	extent	to	which	these	human	reservoirs	contribute	to	the	transmission	of	the	parasite	186 
and	hence	to	gambiense-HAT	persistence	and	potential	resurgence.		187 
Animal	reservoir	188 
Compared	to	latent	infections	in	human,	our	current	knowledge	on	T.b.	gambiense	189 
infections	in	animals	is	very	limited	and	fragmented.	The	presence	of	T.b.	gambiense	in	190 
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animals	has	been	demonstrated	in	a	number	of	studies	(Figure	1)	[30,31].	Several	authors	191 
have	suggested	that	animals	can	act	as	a	reservoir	for	gambiense-HAT	[32-41].	In	192 
rhodesiense-HAT,	sustained	parasite	transmission	cycles	exist	in	both	livestock	and	wildlife,	193 
from	which	the	parasite	can	spill	over	to	humans	[42].	For	T.b.	gambiense,	despite	early	data	194 
generated	on	its	infectivity	and	transmissibility	in	animals,	the	epidemiological	significance	of	195 
any	animal	reservoir	is	not	well	understood	and	may	depend	on	the	specific	ecosystem	of	196 
the	HAT	focus.	Even	if	the	parasite	can	be	transmitted	to	and	from	animals,	factors	such	as	197 
the	proportion	of	blood-feeding	on	that	species	by	tsetse,	will	determine	the	epidemiological	198 
significance	of	the	species	to	act	as	a	maintenance	population	or	part	of	a	maintenance	199 
community.	T.b.	gambiense	can	infect	a	variety	of	domestic	animals	and	wildlife	as	shown	in	200 
Table	1.	Following	infection,	most	of	these	animals	remain	asymptomatic	and	generally	show	201 
low	to	very	low	parasitaemia.	For	instance,	in	pigs	infected	with	a	T.b.	gambiense	strain	202 
isolated	from	a	human	patient,	only	xenodiagnosis	and	blood	culture	succeeded	in	revealing	203 
an	infection	but	conventional	microscopy	failed	to	detect	parasites	[43-47].	Moreover,	204 
experimental	studies	have	shown	that	human-derived	T.b.	gambiense	strains	that	were	205 
cyclically	transmitted	by	tsetse	flies	between	animals	for	more	than	a	year,	remained	206 
transmissible	to	humans	[44].	207 
Studying	natural	T.b.	gambiense	infections	in	animals	is	challenging.	Major	drawbacks	are	208 
the	usually	low	parasitaemia	and	the	necessity	to	distinguish	T.b.	gambiense	from	other	209 
trypanosome	species	such	as	T.	brucei	brucei,	T.	congolense,	T.	vivax,	T.	suis,	and	T.	simiae.	In	210 
particular,	T.b.	gambiense	is	morphologically	identical	to	the	non-human	infective	T.b.	211 
brucei.	Among	the	molecular	tests,	only	those	targeting	the	single-copy	TgsGP	gene	are	212 
gambiense-specific	thus	limiting	its	analytical	sensitivity	to	>100	trypanosomes	per	ml	of	213 
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blood	[48,49].	Biochemical	assays	such	as	isoenzyme	profiling	are	only	applicable	on	parasite	214 
strains	that	have	been	isolated	and	adapted	to	laboratory	rodents	or	to	in	vitro	cultures	[50-215 
52]	and	phenotypic	assays	such	as	the	Blood	Incubation	Infectivity	Test	are	only	readily	216 
applicable	on	isolated	strains	and	are	not	fully	gambiense-specific	[53].	Tests	that	detect	217 
antibodies	against	gambiense-specific	antigens	such	as	the	Variant	Surface	Glycoproteins	218 
(VSG)	LiTat	1.3	and	LiTat	1.5	may	be	more	useful	in	revealing	T.b.	gambiense	infections	in	219 
animals.	However,	the	immune	trypanolysis	test	(TL)	which	is	considered	100%	specific	in	220 
humans	still	has	to	be	validated	in	different	species	of	animals.	Ancillary	information	on	the	221 
T.b.	gambiense	animal	reservoir	can	be	drawn	from	analysing	T.b.	gambiense	infection	in	222 
tsetse,	in	combination	with	its	feeding	behaviour	to	assess	the	vectorial	transmission	of	the	223 
parasite	from	the	animal	reservoir	to	humans	[54].	In	summary,	there	is	a	need	to	further	224 
improve	our	tools	and	increase	our	understanding	regarding	the	importance	of	an	animal	225 
reservoir	in	gambiense-HAT	epidemiology.	If	further	evidence	indicates	that	an	animal	226 
reservoir	may	threaten	gambiense-HAT	elimination,	synergy	with	the	control	of	animal	227 
African	trypanosomiasis	should	be	considered	[55].	228 
Filling	the	knowledge	gaps	229 
The	presence	of	a	reservoir	is	a	critical	obstacle	to	the	sustained	elimination	of	any	infectious	230 
agent	[56].	For	example,	when	the	Guinea	worm	eradication	programme	was	rolled	out,	the	231 
possibility	of	an	animal	reservoir	was	initially	overlooked,	but	the	recent	finding	of	Guinea	232 
worm	infections	in	dogs	led	to	the	hypothesis	that	dogs	could	have	acted	as	a	reservoir	that	233 
caused	the	reappearance	of	human	cases	in	Chad	[57].	The	existence	of	a	human	reservoir,	234 
in	the	form	of	post-kala-azar	dermal	leishmaniasis	and	possibly	also	latent	infections,	is	a	235 
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major	challenge	for	the	sustained	elimination	of	visceral	leishmaniasis	(VL)	from	the	Indian	236 
subcontinent	[58].	237 
The	importance	of	investigating	how	HAT	can	re-emerge	in	so-called	silent	foci	is	clearly	238 
illustrated	by	the	fact	that	a	nine-year	old	child	was	diagnosed	with	gambiense-HAT	in	Ghana	239 
in	2013,	ten	years	after	the	last	detected	case	[59].	Also,	the	finding	of	a	gambiense-specific	240 
PCR	positive	squirrel	in	Equatorial	Guinea	on	Luba	island	in	2014	where	the	last	human	HAT	241 
case	was	reported	in	1995	is	worrying	[39].	Therefore,	in	the	context	of	gambiense-HAT	242 
elimination,	a	key	question	is	whether	human	and/or	animal	reservoirs	are	capable	of	243 
maintaining	transmission	and	causing	resurgence	of	the	disease	in	different	geographical	244 
areas	and	epidemiological	settings	(see	Outstanding	Questions).		245 
As	with	the	mathematical	modelling	of	other	neglected	tropical	diseases	[60],	models	on	246 
HAT	epidemiology	may	help	to	improve	our	epidemiological	knowledge	and	inform	247 
elimination	strategies.	Models	can	explore	if,	and	how,	animal	and	human	reservoirs	could	248 
sustain	endemicity	in	HAT	foci	[61].	However,	model	predictions	heavily	depend	on	the	249 
availability	of	accurate	information	for	their	construction,	parameterisation	and	fitting.	To	250 
date,	a	few	models	have	attempted	to	infer	the	contribution	of	reservoirs	in	gambiense-HAT	251 
transmission	maintenance	by	fitting	to	human	epidemiological	data.	Funk	et	al.	[74]	252 
suggested	that	animals	were	necessary	for	persistent	transmission	in	Bipindi	focus	in	253 
Cameroon.	Studies	of	existing	gambiense-HAT	models	in	a	few	foci	(i.e.	D.R.	Congo,	Guinea	254 
and	Chad)	suggest	that	some	type	of	additional	infection	reservoir	is	needed	to	match	the	255 
observed	dynamics	of	reported	HAT	cases	[3,62,63].	This	could	arise	from	another	human	256 
reservoir	(including	undiagnosed	and	latent	infections),	an	animal	reservoir	and/or	257 
heterogeneities	in	human	risk	exposure	and	surveillance	coverage.	A	different	modelling	258 
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exercise	considered	the	implications	on	transmission	and	control	of	whether	animals	259 
function	as	reservoirs	or	as	zooprophylaxis	but	did	not	address	which	was	more	likely	[64].	260 
Due	to	the	current	lack	of	knowledge	surrounding	latently	infected	people	(including	their	261 
frequency,	disease	progression,	their	relative	infectivity	to	tsetse	and	the	duration	of	this	262 
infectious	stage)	modelling	latent	infections	in	humans	is	challenging,	and	these	263 
uncertainties	will	impact	the	models’	predictions.	In	particular,	latent	infections	have	only	264 
been	explicitly	incorporated	in	one	gambiense-HAT	model	and	the	potential	role	of	these	265 
individuals	in	maintaining	transmission	or	hindering	elimination	has	yet	to	be	fully	analysed	266 
[65].	Arguably	long	duration	infections,	which	eventually	progress	to	late	stage	disease,	are	267 
captured	by	the	stage	1	exponential	distributions	used	in	many	modelling	frameworks,	but	268 
modifications	could	better	represent	self-cure	and	non-detection	of	latent	infections	in	269 
active	screening.	Many	recent	modelling	studies	have	concluded	existing	vector	control	270 
methods	have	the	ability	to	quickly	reduce	transmission	to	and	from	tsetse	to	all	hosts	and	271 
may	be	critical	for	elimination	in	regions	where	reservoirs	exist	[62-67].	272 
New	data	and	investigations	into	latent	human	infections	and	animal	infections	will	help	273 
shape	the	way	in	which	future	models	are	developed	and	parameterised	by	factoring	in	274 
improved	biological	evidence.	Some	key	gaps	in	our	knowledge,	which	influence	modelling	275 
choices,	are	shown	in	Figure	2,	Key	Figure.	As	well	as	refining	formulation	and	276 
parameterisation	of	the	existing	deterministic	models,	it	is	also	clear	that	a	new	generation	277 
of	models	is	needed.	Stochastic	models	are	better	suited	to	capture	the	chance	events	that	278 
determine	the	role	of	cryptic	reservoirs	and	their	implications	for	elimination.	In	conclusion,	279 
improved	mathematical	models	on	HAT	epidemiology	combined	with	additional	field	and	280 
experimental	data	are	needed	to	help	understand	the	respective	roles	of	these	reservoirs.		281 
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Concluding	remarks	282 
We	believe	that	attaining	the	elimination	(zero	transmission)	target	of	gambiense-HAT	by	283 
2030	is	feasible	but,	as	observed	for	other	neglected	tropical	diseases,	latent	infections	-284 
whether	human	or	animal	-	may	constitute	cryptic	parasite	reservoirs	and	thus	add	285 
another	challenge	to	sustained	elimination.	To	inform	evidence-based	elimination	286 
strategies,	a	better	understanding	of	the	contribution	of	these	putative	human	and	animal	287 
reservoirs	on	the	epidemiology	of	gambiense-HAT	is	required,	more	in	particular	on	(1)	288 
the	frequency	and	duration	of	latent	human	infections	and	infections	in	animals,	(2)	the	289 
infectiveness	of	latent	human	infections	and	animal	reservoirs	to	tsetse	flies,	(3)	the	ability	290 
of	latent	human	infections	or	animal	reservoirs	to	sustain	transmission	in	inter-epidemic	291 
periods,	and	(4)	the	possible	existence	of	an	animal	transmission	cycle	in	the	absence	of	292 
human	transmission	and	its	ability	to	seed	a	new	transmission	cycle	in	humans.	To	293 
investigate	these	issues,	we	urgently	need	to	improve	our	toolbox	for	the	identification	of	294 
latent	and	self-cured	infections,	including	prognostic	and	diagnostic	markers.	Also,	more	295 
accurate	and	preferably	high-throughput	tests	to	detect	and	monitor	T.b.	gambiense	296 
infections	in	animals	should	be	developed,	along	with	improved	mathematical	models	for	297 
exploration	of	epidemiological	hypotheses.	298 
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Table	1:	Animals	successfully	infected	with	T.b.	gambiense	strains	isolated	from	human	patients.		492 
Animal	species	 Origin	of	trypanosome	
straina	
Infectiveness	
to	tsetse	
Minimum	observed	duration	
of	infection	
References	
Domestic	animals	
Cat	 Senegambia	and	Congo	
Free	State	
Not	tested	 12	days	 [68]	
Cattle	 Nigeria	 Yes	 50	days	 [69,70]	
Chicken	 Unknown	 Not	tested	 75	days	 [71]	
Dog	 Senegambia	and	Congo	
Free	State,	Nigeria;	
Belgian	Congo	
Yes	 109	days	 [32,44,68]	
Donkey	 Senegambia	 Not	tested	 14	days	 [68]	
Goat	 Senegambia,	Nigeria,	
Belgian	Congo	
Yes	 13	months	 [44,68,69]	
Horse	 Senegambia	 Not	tested	 5	months	 [68]	
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Pig	 Côte	d’Ivoire,	Congo	
Belge,	Nigeria	
Yes	 18	months	 [43,47,72]	
Sheep	 Côte	d’Ivoire	 Not	tested	 	 [73]	
Primates	
Agile	mangabey	(Cercocebus	galeritus	
agilis)	
	
Belgian	Congo	 Yes	 	 [44]	
Green	monkey	(Cercopithecus	
callitrichus,	C.	aethiops	tantalus)	
Congo	Free	State,	
Nigeria	
Yes	 3	months	 [32,68]	
Wolf's	mona	monkey	(Cercopithecus	
wolfi)	
Congo	Belge	 Yes	 15	days	 [43]	
Patas	monkey	(Erythrocebus	patas	
patas)	
Nigeria	 Yes	 3	months	 [32,74]	
Rhesus	macaque	(Macacus	rhesus)	 Senegambia	and	Congo	
Free	State	
Not	tested	 1	month	 [68]	
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Chimpanzee	(Pan	satyrus,	Pan	
troglodytes	verus)	
Senegambia,	Nigeria	 Not	tested	 17	months	 [68,74,75]	
Dwarf	galago	(Galagoides	demidovii)	 République	populaire	du	
Congo	
Not	tested	 28	days	 [76]	
Ungulates	
Bay	duiker	(Cephalopus	dorsalis)	 Belgian	Congo	 Yes	 24	months	 [44]	
Waterbuck	(Kobus	ellipsiprymnus)		 Uganda		 Not	tested	 	 [46]	
Reedbuck	(Redunca	redunca)	 Uganda	 Yes	 15	months	 [46]	
Bushbuck	(Tragelaphus	spekei)	 Uganda	 Yes	 22	months	 [46]	
Rodents	
Gambian	pouched	rat	(Cricetomys	
gambianus)	
République	populaire	du	
Congo	
Yes	 154	days	 [33,76,77]	
Thicket	rat	(Thamnomys	rutilans),	
Jackson's	praomys	(Praomys	
jacksoni),	African	marsh	rat	(Dasymys	
République	populaire	du	
Congo	
Not	tested	 131	days	 [76]	
25 
 
incomtus),	Striped	grass	mouse	
(Lemniscomus	striatus),	Rusty-nosed	
rat	(Cenomys	hypoxanthus),	African	
brush-tailed	porcupine	(Atherurus	
africanus)	
a For	reasons	of	traceability,	we	use	the	name	of	countries	and	the	scientific	name	of	animals	as	mentioned	in	the	original	publication:	Senegambia	=	Senegal	and	493 
The	Gambia;	Belgian	Congo,	Congo	Free	State	and	Congo	Belge	=	Democratic	Republic	of	the	Congo;	République	populaire	du	Congo	=	Republic	of	the	Congo. 494 
 495 
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Box	1:		 Diversity	in	outcomes	of	human	Trypanosoma	brucei	gambiense	infections	496 
There	is	growing	evidence	that	infection	with	T.b.	gambiense	does	not	always	follow	the	497 
classical	course	of	the	disease,	i.e.	a	first	haemo-lymphatic	stage	followed	by	a	second	stage	498 
with	central	nervous	system	involvement	progressing	to	death	if	left	untreated	(see	Figure	499 
I).	These	symptomatic	HAT	patients	are	characterised	by	the	detection	of	parasites	in	any	500 
body	fluid	(P+),	detection	of	specific	antibodies	against	T.b.	gambiense	Variable	Antigen	501 
Type	LiTat	1.3	or	LiTat	1.5	in	immune	trypanolysis	(TL+),	and	the	presence	of	clinical	502 
symptoms.	However,	long-term	follow-up	studies	in	West	Africa	have	shown	that	a	number	503 
of	infected	individuals	do	not	develop	the	disease	and	can	be	classified	as	having	latent	504 
infections	(i.e.	they	are	healthy	carriers)	[7].	They	remain	asymptomatic	without	detectable	505 
parasites	(P-)	for	several	years,	although	they	are	consistently	positive	in	the	immune	506 
trypanolysis	test	(TL+).	Moreover,	some	of	them	may	become	immune	trypanolysis	negative	507 
(TL-)	over	time	suggesting	that	they	self-cured	and	therefore	cannot	transmit	the	parasite	508 
anymore.	509 
	 	510 
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	512 
Figure	1:	Trypanosoma	brucei	gambiense	in	non-human	mammals.	Map	showing	513 
gambiense-human	African	trypanosomiasis	in	endemic	countries	and	sites	where	T.	b.	514 
gambiense	infection	in	non-human	mammals	has	been	investigated	with	direct	and	indirect	515 
methods.	Circles	represent	direct	or	indirect	evidence	of	presence	(red)	and	of	absence	516 
(green)	of	T.b.	gambiense	in	the	period	1990-2016.	For	this	period,	data	are	mapped	at	the	517 
village/site	level.	(Blue)	stars	represent	presence	of	detection	in	the	years	prior	to	1990.	For	518 
this	period,	data	are	mapped	at	the	country	level.	All	source	references	are	provided	as	519 
Supplemental	Information.	520 
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	521 
Figure	2,	Key	Figure:		Unknown	elements	in	human	African	trypanosomiasis	progression	522 
and	transmission.	Solid	lines	represent	progression	between	disease	states,	and	dashed	523 
lines	represent	transmission	of	the	parasites	to	and	from	the	tsetse	vector.	Red	boxes	524 
denote	people	or	animals	that	may	be	infective	to	tsetse,	with	the	darker	shades	denoting	525 
possible	greater	infectiveness.	The	figure	highlights	key	unknown	elements	in	disease	526 
progression	and	transmission	including:	(1)	the	probability	of	an	infection	leading	to	latent	527 
or	stage	1	disease	in	humans;	if,	and	how	frequently,	(2)	self-cure	of	infected	humans	or	(3)	528 
animals	arises,	(4)	the	duration	of	latent	infection	in	humans	or	(5)	any	infections	in	animals,	529 
29 
 
and	(6)	the	relative	probability	of	transmission	to	tsetse	from	different	types	of	infections	530 
(accounting	for	host	feeding	preferences).	531 
	532 
	533 
Figure	I	(Box	1):	Outcomes	of	human	infection	with	Trypanosoma	brucei	gambiense.	534 
When	naïve	persons	(Uninfected),	without	specific	antibodies	(TL-)	and	without	parasites	(P-535 
)	get	infected	with	T.b.	gambiense,	they	undergo	an	early	phase	of	the	disease	with	536 
detectable	parasitaemia	(P+)	but	without	detectable	specific	antibodies.	Thereafter,	most	of	537 
them	develop	the	disease	(HAT	patient)	and	are	characterised	by	specific	antibodies	(TL+)	538 
and	detectable	parasitaemia	(P+).	Some	remain	asymptomatic	(Latent	infection)	with	539 
detectable	specific	antibodies	but	without	detectable	parasites	(TL+,	P-).	Evidence	for	self-540 
cure	comes	from	asymptomatic	people	that	also	eventually	become	negative	for	specific	541 
antibodies	(TL-,	P-).	542 
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Glossary	545 
Anthroponotic	disease:	an	infectious	disease	typically	transmitted	from	human	to	human	546 
(including	through	an	insect	vector).		547 
Blood	Incubation	Infectivity	Test:	T.b.	gambiense	and	T.b.	rhodesiense	have	developed	548 
mechanisms	to	withstand	lysis	by	normal	human	serum,	in	contrast	with	animal	infective	549 
trypanosomes	like	T.b.	brucei,	T.	congolense,	T.	vivax.	To	confirm	that	an	animal	is	infected	550 
with	T.b.	gambiense	or	T.b.	rhodesiense,	its	blood,	or	trypanosomes	isolated	from	that	551 
animal,	are	incubated	with	human	blood	or	serum	where	after	this	mixture	is	injected	in	a	552 
susceptible	animal.	Only	human	serum	resistant	trypanosomes	will	be	able	to	initiate	an	553 
infection	in	the	susceptible	animal.	554 
CATT/T.b.gambiense:	Card	Agglutination	Test	for	Trypanosomiasis	is	an	agglutination	test	555 
for	detection	of	gambiense-specific	antibodies	in	blood.	It	was	the	first	field-applicable	556 
serological	test	introduced	in	the	1980s	for	large-scale	screening	of	populations	at	risk	for	557 
gambiense-HAT.	558 
Deterministic	mathematical	model:	Deterministic	models	ignore	the	impact	of	random	559 
events,	instead	capturing	average	disease	dynamics,	so	that	multiple	simulations	with	the	560 
same	parameter	values	and	initial	conditions	will	lead	to	exactly	the	same	outcome.		561 
Elimination	of	gambiense-HAT:	Elimination	is	the	reduction	to	zero	of	gambiense-HAT	562 
incidence	in	a	defined	area	as	a	result	of	deliberate	efforts;	measures	to	prevent	re-563 
emergence	are	required.		564 
Elimination	of	gambiense-HAT	as	a	public	health	problem:	90%	reduction	in	areas	565 
reporting	more	than	1	case	in	10,000	compared	to	2000-2004,	and	fewer	than	2,000	566 
annually	reported	cases	globally.	567 
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Eradication	of	gambiense-HAT:	Eradication	is	the	permanent	reduction	to	zero	of	the	568 
worldwide	incidence	of	gambiense-HAT	as	a	result	of	deliberate	efforts;	intervention	569 
measures	are	no	longer	needed.	570 
HAT	focus:	A	geographically	defined	zone	where	transmission	of	HAT	occurs	or	has	571 
occurred,	to	which	a	geographical	name	is	given	(locality,	region	and	river).	572 
Immune	trypanolysis:	Highly	accurate	test	for	gambiense-specific	antibodies,	based	on	573 
antibody-mediated	complement	lysis	of	trypanosomes	exposing	one	single	variant-specific	574 
antigen	on	their	surface.	575 
Latent	infection:	On-going	infection	not	progressing	to	clinical	disease,	that	may	remain	576 
undiagnosed.	577 
Maintenance	community:	One	or	more	populations	which	can	transmit	the	pathogen	and,	578 
together,	can	maintain	the	pathogen		579 
Maintenance	population:	Individual	populations	which	can	transmit	the	pathogen	and	can	580 
also	maintain	the	pathogen	in	the	absence	of	other	reservoir	populations.	581 
Rapid	diagnostic	test	(RDT):	Serological	antibody	or	antigen	detection	test,	conditioned	as	582 
individual	test,	compliant	with	the	ASSURED	criteria	(Affordable,	Sensitive,	Specific,	User-583 
friendly,	Rapid	and	robust,	Equipment-free	and	Deliverable	to	end-users);	RDTs	for	584 
gambiense-HAT	detect	antibodies	against	predominant	gambiense-specific	antigens.	585 
Reservoir:	Host	where	the	pathogen	can	maintain	itself	and	from	where	it	can	be	586 
transmitted	to	another	host;	a	reservoir	host	is	essential	to	sustain	infection.	587 
Self-cure:	Infection	that	is	cleared	by	the	host	without	treatment.	588 
Specificity:	The	specificity	of	a	diagnostic	test	is	the	probability	that	the	test	result	is	589 
negative	when	the	test	person	is	not	infected.	It	is	usually	expressed	as	percentage	and	590 
calculated	by	dividing	the	number	of	test	negatives	by	the	number	of	true	negatives	x	100.	591 
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Stage	determination:	HAT	develops	from	an	early	stage	with	parasites	in	the	peripheral	592 
tissues	towards	a	late	stage	with	parasite	invasion	into	the	central	nervous	system.	593 
Treatment	is	different	for	both	stages,	thus	requiring	stage	determination	before	drug	594 
administration.	Determination	of	the	stage	is	achieved	by	examination	of	the	cerebrospinal	595 
fluid	for	the	presence	of	trypanosomes	and	the	number	of	white	blood	cells.	596 
Stochastic	mathematical	model:	Stochastic	models	include	chance	events	so	that	two	597 
simulations	with	the	same	parameter	values	and	initial	conditions	may	lead	to	different	598 
outcomes.	Chance	events	become	more	important	at	very	low	prevalences	such	as	in	pre-599 
elimination	or	re-emergent	settings.	600 
Variant	Surface	Glycoprotein	(VSG):	In	the	vertebrate	host,	the	cell	surface	of	601 
trypanosomes	is	covered	with	a	layer	of	identical	VSGs	of	one	particular	variant	antigen	type	602 
(VAT),	that	protects	the	trypanosomes	against	innate	immune	defence	mechanisms	of	the	603 
host;	VSGs	are	highly	immunogenic	but	periodic	switches	of	the	VAT	of	the	VSG	coat	604 
(antigenic	variation)	enable	the	trypanosome	to	escape	the	host	humoral	immune	response;	605 
during	the	course	of	the	infection,	the	host	blood	contains	antibodies	against	a	wide	606 
spectrum	of	different	VATs.	607 
Xenodiagnosis:	Diagnostic	method	based	on	detection	of	the	parasite	in	susceptible	vectors	608 
after	they	were	fed	on	an	individual	suspected	of	being	infected	with	the	parasite;	in	HAT,	609 
the	vectors	used	are	teneral	tsetse	flies.	610 
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